These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1385925)

  • 1. Concomitant aspirin treatment abolishes the antiatherosclerotic effects of the calcium channel blocker isradipine mediated by PGI2.
    Pirich C; Lupattelli G; Virgolini I; Keiler A; Gerakakis A; Angelberger P; Sinzinger H
    Agents Actions Suppl; 1992; 37():242-50. PubMed ID: 1385925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin abolishes the decreased low-density lipoprotein (LDL) entry into the rabbit arterial wall induced by the calcium channel blocker isradipine.
    Sinzinger H; Virgolini I; O'Grady J; Keiler A; Lupattelli G; Angelberger P; Molinari E
    Eicosanoids; 1992; 5(1):13-6. PubMed ID: 1419074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diminished extracellular matrix production induced by isradipine, a calcium channel blocker, is completely abolished by cyclooxygenase inhibition.
    Fitscha P; Keiler A; Rauscha F; O'Grady J; Sinzinger H
    Prostaglandins Leukot Essent Fatty Acids; 1992 Apr; 45(4):289-91. PubMed ID: 1534906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isradipine, a calcium-entry blocker, decreases vascular [125-I]low-density lipoprotein entry in hypercholesterolemic rabbits.
    Sinzinger H; Lupattelli G; Virgolini I; Gerakakis A; Fitscha P; Molinari E; Angelberger P
    J Cardiovasc Pharmacol; 1991 Apr; 17(4):546-50. PubMed ID: 1711619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostaglandin I2-mediated upregulation of 125I-LDL-receptor binding by isradipine in normo- and hypercholesterolemic rabbits in vivo.
    Sinzinger H; Lupattelli G; Kritz H; Fitscha P; O'Grady J
    Prostaglandins; 1996 Aug; 52(2):77-91. PubMed ID: 8880894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isradipine inhibits mitotic and proliferative activity in the arterial wall.
    Fitscha P; Rauscha F; O'Grady J; Keiler A; Sinzinger H
    Exp Toxicol Pathol; 1994 Mar; 46(1):75-80. PubMed ID: 8086791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for lipid regression in humans in vivo performed by 123iodine-low-density lipoprotein scintiscanning.
    Pirich C; Sinzinger H
    Ann N Y Acad Sci; 1995 Jan; 748():613-21. PubMed ID: 7695216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandins and arterial wall lipid metabolism--in vitro, ex-vivo and in-vivo radioisotopic studies.
    Sinzinger H; Rogatti W
    J Physiol Pharmacol; 1994 Mar; 45(1):27-40. PubMed ID: 8043908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteration of rat cerebral microvascular eicosanoid formation by isradipine, a calcium channel blocker.
    Sinzinger H; Wasinger T; Böck P; O'Grady J; Peskar BA
    Prostaglandins Leukot Essent Fatty Acids; 1998 Jan; 58(1):1-7. PubMed ID: 9482160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isradipine increases vascular prostaglandin I2-formation while the thromboxane B2-synthesis is diminished.
    Kritz H; Schmid P; Keiler A; O'Grady J; Sinzinger H
    Thromb Res; 1995 Dec; 80(6):483-9. PubMed ID: 8610276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct antiatherogenic activity of isradipine and lacidipine on neointimal lesions induced by perivascular manipulation in rabbits.
    Donetti E; Fumagalli R; Paoletti R; Soma MR
    Pharmacol Res; 1997 May; 35(5):417-22. PubMed ID: 9299204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiatherosclerotic actions of isradipine.
    Sinzinger H; Fitscha P
    J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S29-31. PubMed ID: 1376831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arterial wall rather than platelets is responsible for diminished thrombogenicity during isradipine therapy.
    Sinzinger H; Keiler A; O'Grady J
    J Cardiovasc Pharmacol; 1995 Mar; 25(3):453-8. PubMed ID: 7769812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isradipine: a potent calcium blocker with beneficial effects on platelet function and vascular prostacyclin production.
    Weiss K; Fitscha P; O'Grady J; Sinzinger H
    Thromb Res; 1989 May; 54(4):311-7. PubMed ID: 2527422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the antiatherosclerotic effects of dihydropyridine calcium channel blocker and HMG-CoA reductase inhibitor on hypercholesterolemic rabbits.
    Takayama M; Matsubara M; Arakawa E; Takada C; Ina Y; Hasegawa K; Yao K
    Vascul Pharmacol; 2007 Apr; 46(4):302-8. PubMed ID: 17197250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioligand and functional estimates of the interaction of the 1,4-dihydropyridines, isradipine and lacidipine, with calcium channels in smooth muscle.
    Salomone S; Godfraind T
    Br J Pharmacol; 1993 May; 109(1):100-6. PubMed ID: 8495233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of chronic treatment with the calcium entry blocker, isradipine, on vascular calcium overload produced by vitamin D3 and nicotine in rats.
    Henrion D; Chillon JM; Capdeville-Atkinson C; Atkinson J
    J Pharmacol Exp Ther; 1992 Jan; 260(1):1-8. PubMed ID: 1309868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hypertension with dihydropyridine calcium antagonists and aspirin.
    Tison P; Ulicna L; Jakubovska Z; Oravcova J; Fetkovska N
    Blood Press Suppl; 1994; 1():57-60. PubMed ID: 8205303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible mechanism for the anti-atherosclerotic action of the calcium channel blocker AE0047 in cholesterol-fed rabbits.
    Hayashi K; Imada T; Yamauchi T; Kido H; Shinyama H; Matzno S; Nakamura N; Kagitani Y
    Clin Exp Pharmacol Physiol; 1998 Jan; 25(1):17-25. PubMed ID: 9493553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isradipine decreases arterial thrombogenicity in rabbits. A morphometric and radioisotopic study.
    Fitscha P; Keiler A; O'Grady J; Peskar BA; Sinzinger H
    Thromb Res; 1994 May; 74(3):175-83. PubMed ID: 8042186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.